Author: admin

  • Remembering When NASA Mounted The Space Shuttle Atop A Boeing 747

    Remembering When NASA Mounted The Space Shuttle Atop A Boeing 747

    The Boeing 747 continues to be recognized as one of the most iconic commercial jets of all time. Originally introduced in the 1960s, the game-changing aircraft brought unprecedented capacity, range, and comfort to the commercial aviation industry. After its launch, airlines across the world flocked to the type, with some even continuing to operate it today. The 747 and most of its variants are undoubtedly a major success.

    Launch Customer(s)

    Pan American World Airways

    First Delivery

    January 22, 1970

    Last Delivery

    January 31, 2023

    Number Delivered

    1,573


    While the 747 was a commercial success, it has served important roles in aviation beyond passenger operations. The aircraft was famously operated by the United States’ National Aeronautics and Space Administration (NASA), where two modified 747 variants carried the Space Shuttle, the aircraft used for recurring space travel. NASA’s impressive feat of using the jet comes with several interesting facts and a colorful history, further solidifying that the Boeing 747 was the true Queen of the Skies.

    The Shuttle Carrier Brought The Space Shuttle Back To Florida

    NASA Boeing 747 space shuttle carrier

    Photo: Carla Thomas NASA | Wikimedia Commons

    The Boeing 747s used to carry NASA’s Space Shuttle were known as “Shuttle Carrier” aircraft. The aircraft were used between 1977 and 2012, according to the National Air and Space Museum. The aircraft’s primary purpose was to transport the Space Shuttle from its landing location back to the Kennedy Space Center near Cape Canaveral, Florida. This purpose made the Shuttle Carrier a critical link in NASA’s space flight ambitions.

    Both aircraft involved in the program were modified Boeing 747 jets. The aircraft had to undergo several changes to safely transport such a massive piece of equipment, but still, the jets hold significant resemblance to the base model of the Boeing 747. Both aircraft were Boeing 747-100 variants, according to NASA. The first aircraft in the program was acquired from American Airlines in the mid-1970s, not long after the first Boeing 747 entered commercial service.

    Since the program’s launch, the Shuttle Carrier has become an iconic symbol of the United States’ space exploration aspirations. Though the Space Shuttle, and thus its carriers, are no longer in service, many remember the striking and rather unusual appearance of a 747 lifting off with another aircraft attached to the top of its fuselage. But for that to be possible, the aircraft underwent some major enhancements and modifications to be capable of transporting the Space Shuttle.

    Major Modifications Were Made To The Shuttle Carriers

    NASA Boeing 747 and Space Shuttle Enterprise

    Photo: Udo Haafke | Wikimedia Commons

    Because they were carrying such a large aircraft on top of their fuselages, both Shuttle Carrier jets were given some major enhancements. Three struts and their respective structural strengthening in the aircraft’s interior were placed on top of the Shuttle Carriers. In addition to improving the strength of the fuselage, it provided a place for the orbiter to be attached to the aircraft.

    The engineers also added enhanced horizontal stabilizers for improved directional stability. These were attached to the aircraft’s existing horizontal stabilizers, giving a unique and recognizable look to the aircraft’s tail section. Less visible to the public was the removal of the aircraft’s entire interior and cabin, which was necessary given that the aircraft was coming from a commercial airline.

    More advanced instruments to be used by flight crews were also installed. The primary purpose of these added systems were to monitor electrical loads of the orbiter during ferry flights. All of these changes, while certainly costly, made the 747 capable of carrying the Space Shuttle. Beyond these modifications, the aircraft’s appearance remained remarkably close to a standard Boeing 747.

    Related

    How The Boeing 747 Made A Comeback At Delta Air Lines

    30 years after the carrier initially retired the jumbojet, it made a comeback to its fleet.

    The First Shuttle Carrier Did More Than Ferry Aircraft

    747 SCA

    Photo: NASA | Wikimedia

    While the Shuttle Carrier was immortalized for its role in US space exploration, before it was converted into a ferry aircraft, the first jet in the program was actually used for a different purpose upon its arrival at NASA. According to NASA, the government agency used it to perform a series of flight tests at the Armstrong Research Center in Edweards, California. These tests shaped Federal Aviation Administration regulations that were designed to ensure safety for aircraft operating in wake turbulence.

    The tests focused on the phenomenon of wake turbulence, which is often found in the path of large aircraft. Though typically causing minor bumps, in the right conditions, it could pose a threat to the safety of flights that are following larger aircraft. These tests provided the foundation for new flight procedures for arriving and departing commercial aircraft. While used for NASA, it seems the Shuttle Carrier has also contributed to ensuring daily commercial aircraft operations remain safe.

    Following the aircraft’s time with flight tests focused on wake turbulence, it was sent to Boeing to be modified to carry the Space Shuttle. Though the aircraft had important contributions to the world of aviation, its most popular role would not start until changes were made by its manufacturer. The first Shuttle Carrier was utilized until November 1990, before its replacement aircraft was deployed.

    NASA’s Second Shuttle Carrier Also Logged An Impressive History

    Space-shuttle-Boeing-747

    Photo: NASA

    The second Boeing 747-100 to enter the Shuttle Carrier program was first built in 1973. The jet initially entered service with Japan Airlines, but was ultimately obtained by NASA in 1989. Like with the original 747 Shuttle Carrier, the second aircraft was modified by Boeing. Upon the completion of the necessary modifications, the aircraft was delivered to NASA on November 20, 1990. It would remain with the agency for over two decades.

    The aircraft was officially retired in February 2012, marking the end of an iconic and impressive chapter for NASA and the United States’ space exploration efforts. By the time the aircraft was removed from service, it had completed an impressive amount of work for NASA. Among its achievements were:

    Flight Hours

    33,004

    Flights With Shuttle

    66

    The Shuttle Carrier program proved to be a successful one for NASA, and has demonstrated the impressive capabilities of the Boeing 747 and other modern, commercial jets. Despite the Boeing 747’s success, the aircraft is becoming an increasingly rare sight in the skies across the world. It won’t be much longer before airlines follow NASA’s move and retire the aircraft type entirely.

    Related

    Which Boeing 747 Variant Was Used As The Shuttle Carrier Aircraft?

    Both aircraft were ex-commercial passenger jets.

    The 747 Is An Increasingly Rare Jet

    Lufthansa Boeing 747-8 aircraft

    Photo: Vincenzo Pace | Simple Flying

    Unfortunately for 747 fans, the aircraft is reaching the end of its service life. Though it might take longer for freighter airlines (which have embraced the jet) to completely retire the 747, in the commercial segment of the aviation industry, the aircraft has quickly lost favor. The 747’s four engines make it far less efficient than modern twin-engine jets, leading airlines to retire their fleets of the Queen of the Skies in favor of smaller, more cost-efficient aircraft.

    Though the 747’s reign is coming to an end, it boasts a long and successful career in connecting the world. Some of the 747’s largest passenger operators over its lifespan include Japan Airlines, British Airways, Singapore Airlines, and United Airlines. Additionally, major cargo carriers like Atlas Air and Kalitta Air invested heavily in the type.

    The 747 has become an iconic aircraft that revolutionized flying. Though it may soon disappear from the skies, it will likely be remembered for years to come. Countless 747s are displayed in museums across the world, keeping the memory of the famous jet alive. Additionally, for fans of the 747, Lego recently released a new set featuring the 747’s role as a Shuttle Carrier.

    747 Fans Can Now Purchase A Lego Shuttle Carrier Model

    Screenshot 2025-06-24 211837

    Photo: Lego

    Fans of NASA, Lego, or the 747 might enjoy one of Lego’s newest products: a replica of the Shuttle Carrier. The set comes with the pieces to assemble both the 747-100 and Space Shuttle, unlocking a new way to preserve and appreciate the aircraft’s legacy. This set costs about $230 and comes with a whopping 2,417 pieces.

    This isn’t the first tribute to modern aviation Lego has made. The company already sells a Concorde model, immortalizing the only supersonic passenger jet. Lego fans have embraced the kit, potentially paving the way for more aviation-themed Lego sets. The price of the Shuttle Carrier set also indicates Lego’s confidence in demand and excitement for the product.

    This Lego set, among countless other memorials to the Shuttle Carrier and the Boeing 747, demonstrates the widebody aircraft’s role in shaping modern travel and even space exploration. As the jet continues to be retired by commercial carriers, many are still celebrating the aircraft’s contributions to modern travel. Whether it’s displays in museums, Lego kits, or other experiences, the legacy of the Boeing 747 and the Shuttle Carrier is being kept alive by fans and stakeholders across the world.

    Continue Reading

  • Happy return for Sabalenka – Wimbledon

    1. Happy return for Sabalenka  Wimbledon
    2. Wimbledon 2025: How to watch The Championships tennis tournament today, full TV schedule and more  Yahoo Sports
    3. Wimbledon 2025 schedule: How to watch as singles matches begin  ABC News – Breaking News, Latest News and Videos
    4. Carson Branstine, the surprise of the Wimbledon qualifying who funds her career through modelling  claytenis.com
    5. Sabalenka cruises on Wimbledon’s hottest opening day as Alcaraz launches title bid  nation.com.pk

    Continue Reading

  • Pakistan clinch victory against Japan 79-39

    Pakistan clinch victory against Japan 79-39

    A Japanese player attempts to pass the ball to a teammate while Pakistani players try to intercept during the Asian Youth Girls Netball Championship at Jeonju, South Korea, on June 30, 2025. — Reporter

    JEONJU: Pakistan defeated Japan with a 79-39 score in the fourth match of the Asian Youth Girls Netball Championship 2025 held at the Jeonju Hwasan Gymnasium in Jeonju-si, South Korea on Monday.

    From the very beginning, Pakistan took control of the game, maintaining a steady lead through all four quarters.

    The first quarter ended with Pakistan ahead 16-9 and by halftime, they had extended their lead to 39-17.

    The momentum continued as Pakistan further widened the gap to 60-26 in the third quarter, eventually sealing the match with a commanding 79-39 victory.

    Standout performances came from Leya Raza Shah, Alisha Naveed, Haleema, Sarina Hussain, Jasmine Farooq, Farah Rasheed, Amani, Parisa, Sumayya Ahmed and Alina, all of whom played exceptionally well and contributed to the team’s emphatic win.

    Officials from the Pakistan Netball Federation, including Chairman Mudassar Arian, President Sameen Malik, and Secretary General Muhammad Riaz, congratulated the team on their remarkable victory against Japan, praising the players for their skill and teamwork in securing such a convincing result.

    Pakistan are placed in Pool B of the championship and now sit at the top of the group with eight points.

    Their next match is scheduled against the Maldives on Tuesday. The team is set to play five league matches in the group stage.

    The Asian Youth Girls Netball Championship 2025 features a total of 11 participating teams and is being played from June 27 to July four under the supervision of the Asian Netball Federation.

    The teams are divided into two groups. Group A includes Malaysia, Singapore, Sri Lanka, Hong Kong and India.

    While Group B consists of Pakistan, Chinese Taipei, South Korea, Japan, Maldives and Saudi Arabia.


    Continue Reading

  • Action For Humanity statement on atrocities at aid sites in Gaza – ReliefWeb

    1. Action For Humanity statement on atrocities at aid sites in Gaza  ReliefWeb
    2. At least 58 killed as Israel intensifies offensive in Gaza  Australian Broadcasting Corporation
    3. Israel kills nearly 600 Palestinians at aid centres: All you need to know  Al Jazeera
    4. ‘It’s a Killing Field’: IDF Soldiers Ordered to Shoot Deliberately at Unarmed Gazans Waiting for Humanitarian Aid  Haaretz
    5. Israel halts aid into northern Gaza, officials say, clans deny Hamas is stealing it  Reuters

    Continue Reading

  • Gene Haas to drive one of his F1 cars at Goodwood Festival of Speed

    Gene Haas to drive one of his F1 cars at Goodwood Festival of Speed

    Haas have announced that team founder and owner Gene Haas, as well as team boss Ayao Komatsu, will get behind the wheel of Formula 1 machinery at the upcoming Goodwood Festival of Speed.

    After marking their 200th F1 start at the recent Canadian Grand Prix, the US-led operation will continue celebrations with a series of activities at the annual motorsport gathering, which features a world-famous hillclimb.

    This includes Gene Haas driving the 2023-specification VF-23 on Friday, July 11, with Komatsu also making an appearance in the following season’s VF-24.

    Haas revealed that the pair got their first taste of F1 machinery together during a private shakedown at Silverstone a couple of weeks ago, with Gene completing a handful of laps on the Stowe track configuration.

    Kazuki Nakajima, Vice Chairman of Toyota Gazoo Racing Europe, will kick off the four-day event by driving the VF-23 on Thursday, July 10, alongside Komatsu in the VF-24, before full-time Haas drivers Ollie Bearman and Esteban Ocon take over weekend driving duties.

    Alongside their hillclimb activities, Haas will have a strong presence within the Ballroom Paddock, showcasing the VF-16 – the team’s first F1 car – as well as the VF-25, which will be raced in the British Grand Prix just a few days before.

    Haas’ activities at Goodwood coincide with the Festival of Speed’s celebration to mark the 75th anniversary of the F1 World Championship – several other teams and drivers up and down the grid are also set to attend the event.

    Continue Reading

  • AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

    AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER| Amgen

    At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone

    THOUSAND OAKS, Calif., June 30, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced the Phase 3 FORTITUDE-101 clinical trial evaluating first-line bemarituzumab plus chemotherapy (mFOLFOX6) met its primary endpoint of overall survival (OS) at a pre-specified interim analysis. 

    Bemarituzumab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in OS as compared to placebo plus chemotherapy in people living with unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer with FGFR2b overexpression and who are non-HER2 positive. FGFR2b overexpression was defined as 2+/3+ staining in ≥10% of tumor cells by centrally performed immunohistochemistry (IHC) testing.

    Gastric cancer is the fifth leading cause of cancer-related death worldwide, with nearly one million new cases and over 650,000 deaths globally each year 1, highlighting a critical unmet medical need.

    “Most patients with gastric cancer are diagnosed at an advanced stage, with poor prognosis, low survival rates and limited therapeutic options,” said Jay Bradner, M.D., executive vice president of Research and Development at Amgen. “These first positive top-line results of an FGFR2b targeted monoclonal antibody from our Phase 3 FORTITUDE-101 study mark a meaningful advance in the development of effective targeted therapy for gastric cancer.”

    The most common treatment-emergent adverse events (>25%) in patients treated with bemarituzumab plus chemotherapy were reduced visual acuity, punctate keratitis, anaemia, neutropenia, nausea, corneal epithelium defect and dry eye. While ocular events were consistent with the Phase 2 experience and observed in both arms, they occurred with greater frequency and severity in the Phase 3 bemarituzumab arm.

    Detailed results from the trial will be shared at a future medical meeting.

    FORTITUDE-101 was conducted with the support of Zai Lab. Zai Lab holds co-development and commercialization rights for bemarituzumab for mainland China, Hong Kong, Macau, and Taiwan.

    A Phase 3 study of bemarituzumab plus chemotherapy and nivolumab is also ongoing in patients with first-line gastric cancer, with a data readout anticipated in H2 2025.

    About FGFR2b 
    The FGFR2b protein (also known as fibroblast growth factor receptor 2b) is an emerging biomarker which, when overexpressed, promotes aberrant signaling leading to tumor cell proliferation.2

    The FGFR2b protein is overexpressed by G/GEJ tumor cells in approximately 38% of patients with advanced G/GEJ cancer. FGFR2b protein overexpression is defined as 2+/3+ staining intensity on tumor cell membrane, as detected by immunohistochemistry (IHC) testing. In approximately 16% of patients with advanced G/GEJ cancer, FGFR2b protein overexpression is observed on ≥10% of tumor cells by IHC.3

    About FORTITUDE-101 
    FORTITUDE-101 is a randomized, multi-center, double-blind, placebo-controlled Phase 3 study of bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line therapy in advanced G/GEJ cancer with FGFR2b overexpression. The FORTITUDE-101 trial spanned 300 sites across 37 countries, with 547 patients enrolled.

    The primary outcome measure of the trial is overall survival in patients with FGFR2b ≥10% 2+/3+ tumor cell staining.  Key secondary outcome measures include progression-free survival and overall response rate. Candidates were excluded from the trial if they were known to be human epidermal growth factor receptor 2 (HER2) positive. FORTITUDE-101 included more comprehensive ocular-related monitoring than previous studies of bemarituzumab.

    About Amgen
    Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world’s toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

    In 2024, Amgen was named one of the “World’s Most Innovative Companies” by Fast Company and one of “America’s Best Large Employers” by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

    For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram,  YouTube and Threads. 

    Amgen Forward-Looking Statements

    This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeOne Medicines Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc. or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon’s business, performance and opportunities, and any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

    No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.

    Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions, including those resulting from geopolitical relations and government actions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our sustainability objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

    The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration, and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

    CONTACT: Amgen, Thousand Oaks Elissa Snook, 609-251-1407 (media)Justin Claeys, 805-313-9775 (investors) 

    REFERENCES

    1. Bray F, et al. CA Cancer J Clin. 2024;74(3);229-263
    2. Wainberg ZA, et al. Lancet Oncol. 2022;23(11):1430-40
    3. Rha SY, et al. JCO Precis Oncol. 2025; 9 (e2400710). DOI:10.1200/PO-24-00710

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-positive-topline-phase-3-results-for-bemarituzumab-in-fibroblast-growth-factor-receptor-2b-fgfr2b-positive-first-line-gastric-cancer-302494006.html

    SOURCE Amgen


    Continue Reading

  • Paul Aron to drive in first practice at Silverstone as Alpine agree deal with Kick Sauber

    Paul Aron to drive in first practice at Silverstone as Alpine agree deal with Kick Sauber

    Alpine Reserve Driver Paul Aron will make his free practice debut at the upcoming British Grand Prix weekend with Kick Sauber after the rival teams came to an agreement to share his driving services.

    The Estonian 21-year-old, who competed in F2 last season, is not racing competitively this year, with his focus currently on helping Alpine with simulator work as they try and claw their way back up the standings from P10 in the Championship.

    Alpine entered the 2025 F1 season with plenty of driving talent in reserve. While Ryo Hirakawa soon departed for Haas, the Enstone-based squad still have Jack Doohan alongside Aron – the Australian had started the year in a full-time race seat but was swapped out in favour of Franco Colapinto ahead of the Emilia-Romagna Grand Prix.

    The agreement Alpine have reached with Kick Sauber will release Aron for two FP1 sessions this season, with every team having to give up four FP1 sessions across the year for a ‘Friday’ driver, unless they are running a rookie in one of their cars.

    Aron will don the black and green of Kick Sauber at Silverstone this weekend, and also at the Hungaroring later this summer. Apart from that, he remains an Alpine driver and will take part in three further FP1 sessions for the French team with dates to be confirmed in due course.

    “I am very pleased to be given the opportunity to have valuable track time in Formula 1, so thanks to BWT Alpine Formula One Team for coming to this arrangement,” Aron said.

    “It is no secret that my desire is to one day race full-time in Formula 1 so any chance to be on track in a competitive environment is an important stepping stone.

    “While I continue to focus on my development with Alpine, I do look forward to the two sessions with Kick Sauber and giving my maximum effort to them at Silverstone and Budapest.”

    Kick Sauber only need to give up two FP1 sessions this season, as they are running a designated rookie in their other car in Gabriel Bortoleto. As such, Aron will replace Nico Hulkenberg at Silverstone and in Budapest.

    “It is in our interests to maximise any driving opportunities for our young talent, so it is good to have an agreement with Sauber for Paul to drive in Free Practice 1 in Silverstone and Budapest,” added Flavio Briatore, Alpine’s Executive Advisor.

    “We are seeing varied success from last year’s Formula 2 drivers this year up and down the grid, and Paul was a front runner in that category, so this is an opportunity for him and the team to continue his progress and to give him valuable track time.”

    Aron finished third in last year’s F2 Championship, behind Bortoleto and Isack Hadjar – both of whom are impressing in their first full season as F1 drivers.

    While teams have often released drivers for these sorts of duties in the past, what makes this agreement rare is the fact that Kick Sauber and Alpine are battling each other in the Championship, Kick Sauber lying ninth in the standings just ahead of Alpine.

    Continue Reading

  • Uncertainty clouds fragile Israel-Iran ceasefire one week in

    Uncertainty clouds fragile Israel-Iran ceasefire one week in





    Uncertainty clouds fragile Israel-Iran ceasefire one week in – Daily Times


































    Continue Reading

  • ‘Dukes of Hazzard’ stunt car jump in Kentucky

    ‘Dukes of Hazzard’ stunt car jump in Kentucky

    A stuntman drove a replica of the “Dukes of Hazzard” General Lee car over a fountain in Somerset, Kentucky, over the weekend, in a feat inspired by the series.

    The stunt took place at the Somernites Cruise, a classic car event, in downtown Somerset on Saturday, June 28. According to local outlets the Lexington Herald Leader and the Commonwealth Journal, 35,000 people were in attendance to watch stunt jumper Raymond Kohn complete his 30th “Dukes of Hazzard” jump over a fountain in the city’s square.

    “It was so popular the first time, people asked me to come back and it became more popular – and I became the go-to-guy to jump the General Lee,” Kohn told the Herald Leader. Kohn later told the outlet he had recently undergone surgery to remove a brain tumor, adding he asked the surgeon, “Will I be able to jump after the surgery?”

    “Dukes” stars John Schneider, who played Bo Duke, and Byron Cherry, who played Coy Duke, were also in attendance at the event.

    “The Dukes of Hazzard,” which ran for 146 episodes across seven seasons, followed the “good ol’” Duke boys of rural Hazzard County, Georgia. Not without its controversies, reruns of the show are few and far between due to its Confederate flag imagery. TV Land dumped the show several years ago, and Warner Bros., which produced the series, halted production of toy replicas of the General Lee, an orange 1969 Dodge Charger stock car driven by rambunctious Southern cousins Luke and Bo. The car famously features an image of the Confederate flag on its roof.

    Continue Reading

  • Hubble Spots Reflection Nebula in Taurus Molecular Cloud

    Hubble Spots Reflection Nebula in Taurus Molecular Cloud

    Astronomers using the NASA/ESA Hubble Space Telescope have produced an outstanding image of the reflection nebula GN 04.32.8.

    This Hubble image shows GN 04.32.8, a reflection nebula some 480 light-years away in the constellation of Taurus. The color composite was assembled from images taken in visible and near-infrared light. It is based on data obtained through two filters. The color results from assigning different hues to each monochromatic image associated with an individual filter. Image credit: NASA / ESA / Hubble / G. Duchêne.

    GN 04.32.8 is located approximately 480 light-years away in the constellation of Taurus.

    Also known as DG 41, it is a small part of the stellar nursery known as the Taurus Molecular Cloud.

    “Reflection nebulae are clouds of dust in space that don’t emit their own light, as other nebulae do,” the Hubble astronomers said in a statement.

    “Instead, the light from nearby stars hits and scatters off their dust, lighting them up.”

    “Because of the way the light scatters, many reflection nebulae tend to appear blue, GN 04.32.8 included.”

    GN 04.32.8 is illuminated by a system of three bright stars in the center of the Hubble image, mainly the variable star V1025 Tauri in the very center.

    “One of those stars overlaps with part of the nebula: this is another variable star that is named HP Tauri, but is classified as a T Tauri star, for its similarity to yet another variable star elsewhere in the Taurus Molecular Complex,” the astronomers said.

    “T Tauri stars are very active, chaotic stars at an early stage of their evolution, so it’s no surprise that they appear in a prolific stellar nursery like this one.”

    “The three stars are also named HP Tau, HP Tau G2 and HP Tau G3; they’re believed to be gravitationally bound to each other, forming a triple system.”

    “Eagle-eyed viewers might notice the small, squashed, orange spot, just left of center below the clouds of the nebula, that’s crossed by a dark line,” the researchers said.

    “This is a newly-formed protostar, hidden in a protoplanetary disk that obstructs some of its light.”

    “Because the disk is edge-on to us, it’s an ideal candidate for study.”

    “We are using Hubble here to examine it closely, seeking to learn about the kinds of exoplanets that might be formed in disks like it.”

    Continue Reading